Skip to main content
Premium Trial:

Request an Annual Quote

NanoString, Riken Genesis to Commercialize Diagnostic Assays in Japan

NEW YORK (GenomeWeb) – NanoString Technologies and Sysmex subsidiary Riken Genesis said today that they have entered into a partnership to bring nCounter-based diagnostic assays to the Japanese market. 

Under the agreement, NanoString and Riken will collaborate to commercialize, register, and gain reimbursement for companion diagnostic tests, including a lymphoma subtyping test that  will be marketed as the nCounter Dx LymphMark assay.

LymphMark is a 20-gene signature that classifies cell-of-origin subtypes in patients with diffuse large B-cell lymphoma (DLBCL). Based on a signature called Lymph2Cx, which was originally developed by the Lymphoma/Leukemia Molecular Profiling Project, the test has already demonstrated analytical robustness and potential clinical utility, NanoString said.

In the US, NanoString has a deal with Celgene, in which the same panel has been used to select patients for the firm's Phase III ROBUST trial of Revlimid (lenalidomide). NanoString has said it anticipates filing a PMA this year with the US Food and Drug Administration for a Lymph2Cx-based CDx to the Celgene drug.

The Lymph2Cx assay is also being tested in more than 40 research studies with 23 other companies, NanoString added.

"Through this collaboration, we will work closely with Riken Genesis to launch novel diagnostic products on the nCounter platform that have the potential to guide decision making in the Japanese oncology community," NanoString CEO Brad Gray said in a statement.

Financial terms of the deal were not disclosed.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.